 |
|
Uterine fibroid shrinkage after short-term use of selective progesterone receptor modulator or gonadotropin-releasing hormone agonist
Min Jin Lee, Bo Seong Yun, Seok Ju Seong, Mi-La Kim, Yong Wook Jung, Mi Kyoung Kim, Hyo Sook Bae, Da Hee Kim, Ji Young Hwang
Obstet Gynecol Sci. 2017;60(1):69-73. Published online 2017 Jan 19 DOI: https://doi.org/10.5468/ogs.2017.60.1.69
|
|
Citations to this article as recorded by
 Molecular subclass of uterine fibroids predicts tumor shrinkage in response to ulipristal acetate
Åsa Kolterud, Niko Välimäki, Heli Kuisma, Joonatan Patomo, Sini T Ilves, Netta Mäkinen, Jaana Kaukomaa, Kimmo Palin, Eevi Kaasinen, Auli Karhu, Annukka Pasanen, Ralf Bützow, Oskari Heikinheimo, Helena Kopp Kallner, Lauri A Aaltonen
Human Molecular Genetics.2023; 32(7): 1063. CrossRef Effectiveness and Safety of Ultrasound-guided Percutaneous Microwave Ablation for a Single Uterine Fibroid Greater than 300 cm3
Jiajun Xia, Dengke Teng, Guoqing Sui, Qiang Luo, Yuanqiang Lin, Hui Wang
Journal of Minimally Invasive Gynecology.2023; 30(4): 290. CrossRef Contemporary approaches in the management of uterine leiomyomas
Shikha Singh, Praveen Kumar, Kavita, Saurabh Singh Rathore, Yashasvi Singh, Neha Garg
European Journal of Obstetrics & Gynecology and Reproductive Biology.2023; 287: 195. CrossRef GnRH agonists and antagonists in therapy of symptomatic uterine fibroids – current roles and future perspectives
Michał Ciebiera, Obianuju Sandra Madueke-Laveaux, Stepan Feduniw, Mara Ulin, Robert Spaczyński, Magdalena Zgliczyńska, Monika Bączkowska, Elżbieta Zarychta, Tomasz Łoziński, Mohamed Ali, Ayman Al-Hendy
Expert Opinion on Pharmacotherapy.2023; 24(16): 1799. CrossRef Ulipristal acetate versus levonorgestrel-releasing intrauterine system for heavy menstrual bleeding: the UCON randomised controlled trial and mechanism of action study
Lucy HR Whitaker, Lee J Middleton, Lee Priest, Smita Odedra, Versha Cheed, Elaine P Nicholls, Alistair RW Williams, Neil Roberts, Clive E Stubbs, Konstantios Tryposkiadis, Hannah Bensoussane, Rohan Chodankar, Alison A Murray, Moira Nicol, Aleksandra O Tso
Efficacy and Mechanism Evaluation.2023; : 1. CrossRef Evidence-Based Management of Uterine Fibroids With Botanical Drugs-A Review
Masita Arip, Vi Lien Yap, Mogana Rajagopal, Malarvili Selvaraja, K Dharmendra, Sasikala Chinnapan
Frontiers in Pharmacology.2022;[Epub] CrossRef What happens after randomised controlled trials? Uterine fibroids and ulipristal acetate: systematic review and meta-analysis of "real-world" data
Neha Shah, Elizabeth Egbase, Michael Sideris, Funlayo Odejinmi
Archives of Gynecology and Obstetrics.2021; 303(5): 1121. CrossRef Effect of Perioperative Transfusion on Postoperative Morbidity Following Minimally Invasive Hysterectomy for Benign Indications
Paul Tyan, Ali Taher, Erin Carey, Richard Amdur, Cole Messersmith, Hannah N. Robinson, Alex Gu, Maria V. Vargas, Gaby N. Moawad
Journal of Minimally Invasive Gynecology.2020; 27(1): 200. CrossRef Differences in fibroid vascularity after three months of pre-treatment with leuprolide acetate or ulipristal acetate: A pilot study
Marissa Frijlingh, Inge De Milliano, Wouter. J.K. Hehenkamp, Judith. A.F. Huirne
European Journal of Obstetrics & Gynecology and Reproductive Biology.2020; 245: 186. CrossRef First Impressions Can Be Deceiving: Surgical Outcomes of Laparoscopic Myomectomy in Patients Pretreated with Ulipristal Acetate
Clarissa Frascà, Alessandro Arena, Eugenia Degli Esposti, Diego Raimondo, Simona Del Forno, Elisa Moro, Margherita Zanello, Mohamed Mabrouk, Renato Seracchioli
Journal of Minimally Invasive Gynecology.2020; 27(3): 633. CrossRef Predictive Factors of Response to Selective Progesterone Receptor Modulator (Ulipristal Acetate) in the Pharmacological Treatment of Uterine Fibroids
Iwona Szydłowska, Aleksandra Marciniak, Jolanta Nawrocka-Rutkowska, Aleksandra Rył, Andrzej Starczewski
International Journal of Environmental Research and Public Health.2020; 17(3): 798. CrossRef Predictors of uterine fibroid volume reduction under ulipristal acetate: a prospective MRI study
Antoine Netter, Vanessa Pauly, Pascale Siles, Audrey Pivano, Vincent Vidal, Aubert Agostini
Reproductive BioMedicine Online.2019; 39(5): 795. CrossRef Potential synergism between ulipristal acetate and vitamin D3 in uterine fibroid pharmacotherapy – 2 case studies
Michał Ciebiera, Błażej Męczekalski, Krzysztof Łukaszuk, Grzegorz Jakiel
Gynecological Endocrinology.2019; 35(6): 473. CrossRef Predictive factor for volume reduction of uterine fibroids after short-term use of ulipristal acetate
Bo Seong Yun, Seok Ju Seong, Yong Wook Jung, Mi-La Kim, Hyo Sook Bae, Mi Kyoung Kim, Sung Shin Shim
European Journal of Obstetrics & Gynecology and Reproductive Biology.2018; 224: 133. CrossRef Is ulipristal acetate the new drug of choice for the medical management of uterine fibroids? Res ipsa loquitur?
Funlayo Odejinmi, Reeba Oliver, Rebecca Mallick
Women's Health.2017; 13(3): 98. CrossRef Medical Management of Symptomatic Fibroids: Worth It?
Chandrashekhar V. Hegde
The Journal of Obstetrics and Gynecology of India.2017; 67(4): 233. CrossRef
|